Abstract: The method for the in vitro or ex vivo amplification of stem cells of brown or beige adipocytes includes: extracting (i) a stromal vascular fraction from human adipose tissue including endothelial cells of the vascular network of human adipose tissue and stem cells of brown or beige human adipose tissue and (ii) an extracellular matrix of the human adipose tissue, the extracellular matrix including endothelial cells of the vascular network of human adipose tissue, stem cells of brown or beige human adipose tissue and collagen; mixing the stromal vascular fraction and the extracellular matrix; and culturing the mixture obtained, in suspension, in a culture medium.
Type:
Application
Filed:
July 15, 2021
Publication date:
September 7, 2023
Applicants:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CHU DE NICE, ETABLISSEMENT FRANCAIS DU SANG, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE COTE D'AZUR, UNIVERSITE TOULOUSE III - PAUL SABATIER
Inventors:
Christian, Jean, Lucien Dani, Vincent Dani, Louis Casteilla, Alain, Pierre, Louis Doglio, Philippe Letertre
Abstract: The present invention relates to the identification of proteins of the WNT signaling pathway as therapeutic targets of pigmentation disorder and as biomarkers of pigmentation status. The invention in particular relates to products and methods for treating a hypopigmentation disorder. The invention also relates to products and methods for detecting, diagnosing, staging or monitoring the course of hypopigmentation disorder and is particularly suited for human subjects.
Type:
Grant
Filed:
December 9, 2020
Date of Patent:
May 16, 2023
Assignees:
INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Côte d'Azur, CHU de Nice
Abstract: The method for tin vitro or ex vivo amplification of human adipose tissue stem cells includes: —extracting a stromal vascular fraction of a human adipose tissue including endothelial cells of the human adipose tissue vascular network and human adipose tissue stem cells, and an extracellular matrix of the human adipose tissue, the extracellular matrix including endothelial cells of the human adipose tissue vascular network, human adipose tissue stem cells and collagen; —mixing the stromal vascular fraction and the extracellular matrix; and—culturing the mixture obtained in the preceding step, in suspension, in a culture medium.
Type:
Application
Filed:
January 13, 2020
Publication date:
March 31, 2022
Applicants:
UNIVERSITÉ CÔTE D'AZUR, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), CHU DE NICE
Inventors:
Christian Dani, Alain Doglio, Vincent Dani-Davesne, Philippe Letertre
Abstract: The present invention relates to the identification of proteins of the WNT signaling pathway as therapeutic targets of pigmentation disorder and as biomarkers of pigmentation status. The invention in particular relates to products and methods for treating a hypopigmentation disorder. The invention also relates to products and methods for detecting, diagnosing, staging or monitoring the course of hypopigmentation disorder and is particularly suited for human subjects.
Type:
Grant
Filed:
December 16, 2015
Date of Patent:
April 20, 2021
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ CÔTE D'AZUR, CHU DE NICE
Abstract: Disclosed is a method for assessing the prognosis of idiopathic membranous nephropathy in a body fluid sample from a human subject, based on profiling PLA2R1 epitopes recognized by autoantibodies in the sample. The method further relates to analysis of PLA2R1 epitope spreading amongst three PLA2R1 domains (Cys R, CTLD1 and CTLD7) that are recognized by anti-PLA2R1 autoantibodies, two of which (CTLD1 and CTLD7) are more closely associated with active idiopathic membranous nephropathy and likely linked by a mechanism of epitope spreading.
Type:
Grant
Filed:
July 8, 2016
Date of Patent:
August 11, 2020
Assignees:
Université de Nice Sophia Antipolis, Centre National de la Recherche Scientifique (CNRS), CHU de Nice
Inventors:
Vincent Louis Marie Esnault, Barbara Polski, Gérard Jean Frantz Lambeau, Guillaume Dolla
Abstract: The present invention relates to the identification of the glycogen synthase kinase-3 beta (GSK3B or GSK-3P) as a therapeutic target of pigmentation disorder and as biomarker of pigmentation status. The invention in particular relates to products and methods for treating a hypopigmentation disorder. The invention also relates to products and methods for detecting, diagnosing, staging or monitoring the course of hypopigmentation disorder and is particularly suited for human subjects.
Type:
Grant
Filed:
December 16, 2015
Date of Patent:
April 28, 2020
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITY DE NICE SOPHIA ANTIPOLIS, CHU DE NICE
Abstract: An anastomotic connector is disclosed that includes a connector body having a first end engageable into a first vessel, the first end being provided with teeth on its outer surface, and a first locking sleeve engageable around the first end, the first locking sleeve surrounding the teeth in a locked position, in order to impede relative movement between the first vessel and the connector body. The first locking sleeve is provided with longitudinal ribs on its inner surface, the ribs being spaced from each other in a circumferential direction of the first locking sleeve.